[Article]: What's the True Cost of a Misaligned Pharma Automation Project?

A pharmaceutical automation project that overruns its budget often traces back to a control system that never matched actual production requirements. That mismatch tends to surface during commissioning, forcing costly rework and pushing back regulatory approval for production. Selecting a qualified pharmaceutical automation systems integrator before signing a contract heads off that outcome. Waiting until a project stalls turns the same vetting process into expensive repair work.

Why Pharma Automation Projects Go Off Track

Misalignment in a pharmaceutical automation project often begins with user requirement specifications that leave too much room for interpretation. Vague or incomplete requirements lead engineering teams to discover gaps mid-build, forcing design revisions after development has started and adding unplanned time and expense.

Coordination breakdowns between automation engineers and quality assurance teams create a second common failure point. Validation gaps left unaddressed early tend to surface once commissioning begins, pushing back production readiness and adding cost.

Audit trail functionality shows what is at stake when a system is not properly validated. Federal regulation 21 CFR Part 11, Section 11.10(e), addresses this risk directly. It requires a secure and time-stamped log of who did what and when for systems that create, modify or delete electronic records. Falling short can create compliance exposure and costly remediation work.

Building a Pharmaceutical Automation Systems Integrator Selection Checklist

Avoiding these costly outcomes starts before a contract gets signed, with a checklist built around four core pillars. That list begins with Control Systems Integrators Association (CSIA) certification. Each pillar addresses a distinct area of risk, giving manufacturers a structured way to evaluate a prospective partner:

• CSIA certification: Independent audit verification that an integrator meets established business and project management standards.

• Validation and compliance expertise: Proven capability to produce the computer system validation documentation that regulators expect.

• Batch process expertise: Demonstrated experience applying standardized batch control models to pharmaceutical production.

• Life cycle support: Long-term technical support and change control processes that protect system performance after commissioning.

1. Verifying a CSIA-Certified Systems Integrator

Certification from CSIA offers a useful starting point for narrowing a list of potential partners. Working with a CSIA-certified systems integrator means the firm has passed a third-party audit of its business practices. That audit confirms its project management, quality assurance and financial controls meet established benchmarks, going beyond technical skill alone.

Huffman Engineering illustrates what that distinction looks like in practice. Its certification history dates back to 2005, with CSIA recertification every three years to keep the designation active. Its project portfolio spans pharmaceutical plants, electrical utilities and food and beverage producers. That track record shows an integrator that adheres to established industry benchmarks over multiple audit cycles.

2. Confirming Computer System Validation and Compliance Expertise

CSIA certification confirms how an integrator runs its business, but the second pillar demands proof of regulatory competence. Pharmaceutical manufacturers must prove a regulated automation system performs as intended, and that proof is where Computer System Validation (CSV) expertise becomes essential. An integrator without real CSV experience may deliver a system that works in practice, but cannot withstand the scrutiny a Food and Drug Administration (FDA) audit demands.

Malisko Engineering offers a clear example of this expertise in the life sciences space. The firm works with pharmaceutical and other regulated life sciences manufacturers. It handles change control, compliance documentation and validation work to lower risk and keep production efficient.

As part of its CSV process, Malisko builds the full validation paper trail that regulators expect. That trail includes a Validation Master Plan, test plans, qualification protocols and summary reports tied to FDA compliance.

Pharmaceutical manufacturing often involves narrow tolerances where a small variation can compromise an entire batch. That risk is why documented testing before production release carries so much weight. The manufacturing process, according to Malisko, is "intricate, sensitive and can be unstable from a quality standpoint."

3. Assessing ISA-88 Batch Control and Process Expertise

Validated systems still need batch-specific expertise, the third pillar of this checklist. Batch production introduces complexity that calls for automation expertise built around recipe-driven manufacturing, since pharmaceutical products often run multiple variations on the same equipment.

The International Society of Automation (ISA) developed the ISA-88 batch standard, adopted by the American National Standards Institute. It gives batch manufacturers a shared set of terms and documentation practices for recipes and procedures. That framework helps auditors and regulators trace exactly how a given batch was produced.

Bachelor Controls offers a clear example of a specialist built around this discipline. Since 1983, the company has focused on batch control and process automation across food, beverage and pharmaceutical production. Its designs follow the ISA-88 model for consistent recipe structures.

The company also connects plant floor batch execution to enterprise resource planning systems. The data syncs both ways, generating yield reports and maintaining electronic batch records.

4. Evaluating Long-Term Life Cycle Support and Partnership Fit

Certification, validation and batch expertise lead to what happens after commissioning, forming the fourth and final pillar. A validated pharmaceutical automation system needs ongoing technical support to maintain that status as production requirements shift. Software patches and recipe changes can all put compliance at risk without a documented change control process.

Manufacturers evaluating a CSIA-certified systems integrator should ask about response time commitments and how change requests get documented after go-live. A support partner with clear answers tends to reduce production disruptions whenever a system needs modification.

Frequently Asked Questions

Choosing the right pharmaceutical automation systems integrator often raises a handful of recurring questions as manufacturers compare vendors. The answers below revisit the core criteria already covered.

What does CSV involve for pharmaceutical automation?

CSV demonstrates, through documented testing, that a regulated automation system meets its specified requirements before entering production use. That process typically includes a Validation Master Plan, functional specifications and executed qualification protocols — the deliverables discussed above.

Why does ISA-88 batch control matter for pharma manufacturers?

ISA-88 matters because it gives pharmaceutical manufacturers a standardized model for organizing batch operations across recipes and procedures. That shared structure supports consistent recipe execution and gives auditors a traceable record of how each batch was produced.

What questions should manufacturers ask a CSIA-certified automation integrator?

Manufacturers should ask for current proof of CSIA certification along with examples of regulated pharmaceutical projects completed. It is also worth asking what validation deliverables the integrator typically produces and whether the team has ISA-88 experience.

Make the Next Pharma Automation Investment Pay Off

Poor integration decisions rarely show up as a single cost. They compound through redesign work and compliance exposure that can follow a facility for years. Working through the four pillars covered here before committing to a pharmaceutical automation systems integrator gives manufacturers a structured way to protect that investment.